Show simple item record

dc.contributor.authorMcCormick, C.A
dc.contributor.authorMulvany, L
dc.contributor.authorDe Tavernier, M.C
dc.date.accessioned2019-06-13T15:15:02Z
dc.date.available2019-06-13T15:15:02Z
dc.date.issued2019-04
dc.identifier.urihttp://hdl.handle.net/10147/624725
dc.description.abstractThe use of anti-D to prevent haemolytic disease of the new-born can be regarded as one of the greatest success stories of modern medicine. Rhesus antibodies cause significant harm to rhesus positive foetuses in utero including anaemia, jaundice, hydrops fetalis and stillbirth. Deaths due to haemolytic disease of the new born have fallen dramatically. In the UK 1 in 2180 babies in 1953 died due to Rhesus haemolytic disease. 37 years later, in 1990, this figure had dropped to 1 in 62,500 1. Recent initiatives including the routine administration of anti-D at 28-32 weeks gestation have further reduced the incidence of sensitisation2.en_US
dc.language.isoenen_US
dc.publisherIrish Medical Journalen_US
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/us/*
dc.subjectBLOOD DISORDERSen_US
dc.subjectIMMUNE SYSTEMen_US
dc.titleTargeted Anti-D, The First Irish Perspectiveen_US
dc.typeArticleen_US
dc.identifier.journalIrish Medical Journalen_US
dc.description.fundingNo fundingen_US
dc.description.provinceConnachten_US
dc.description.peer-reviewpeer-reviewen_US
refterms.dateFOA2019-06-13T15:15:02Z


Files in this item

Thumbnail
Name:
art8.html
Size:
28.55Kb
Format:
HTML
Description:
Main Article

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivs 3.0 United States
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 United States